Research News
SELECT found fewer cardiovascular events with semaglutide 2.4 mg. The population was narrow.
In adults with cardiovascular disease and overweight or obesity, and without diabetes, weekly semaglutide 2.4 mg…
Section
Research News
Reviews, registries, and trial reports before they are paraphrased.
Research News
FLOW tested semaglutide 1 mg in diabetic kidney disease, not the obesity dose
Perkovic and colleagues reported fewer major kidney-disease events with weekly semaglutide 1 mg in adults who…
Research News
Orthopaedic review of BPC-157 finds the human evidence is still a footnote
A systematic review kept 36 studies. Thirty-five were preclinical. The remaining clinical report was a 12-person…
Research News
Retatrutide’s phase 2 obesity trial is a drug study, not a catalog code
The New England Journal of Medicine phase 2 trial tested a triple hormone-receptor agonist. Research vials…
Research News
A MOTS-c analogue has a first-in-human record. Efficacy is still thin.
CB4211, an analogue of the mitochondrial peptide MOTS-c, was taken into a phase 1 study in…